Journal article
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy
TM Mota, TA Rasmussen, A Rhodes, S Tennakoon, A Dantanarayana, F Wightman, M Hagenauer, J Roney, T Spelman, DFJ Purcell, J McMahon, JF Hoy, HM Prince, JH Elliott, SR Lewin
AIDS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017
Abstract
Objective: To determine the long-term effects of vorinostat on safety and virological parameters in HIV-infected individuals on suppressive antiretroviral therapy (ART). Design: Prospective longitudinal observational extended follow-up of 20 HIV-infected individuals on ART previously enrolled in a clinical trial of daily vorinostat 400 mg for 14 days. Extended follow-up included visits at 6, 12, 18 and 24 months postenrolment in the initial clinical trial. Methods: Cell-associated unspliced HIV RNA, total HIV DNA and plasma HIV RNA were quantified by PCR, and CD4+ and CD8+ T cells quantified by flow cytometry. Changes over time in each parameter were assessed using the Wilcoxon matched pair ..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
The work was supported by an investigator initiated grant from Merck. Other sources of support included the National Health and Medical Research Council (NHMRC) of Australia and the National Institutes for Health U19 AI096109. SRL is an NHMRC Practitioner Fellow.